KR100899848B1 - 폐암 진단용 마커 - Google Patents
폐암 진단용 마커 Download PDFInfo
- Publication number
- KR100899848B1 KR100899848B1 KR1020080070849A KR20080070849A KR100899848B1 KR 100899848 B1 KR100899848 B1 KR 100899848B1 KR 1020080070849 A KR1020080070849 A KR 1020080070849A KR 20080070849 A KR20080070849 A KR 20080070849A KR 100899848 B1 KR100899848 B1 KR 100899848B1
- Authority
- KR
- South Korea
- Prior art keywords
- protein
- precursor
- isoform
- lung cancer
- hypothetical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title abstract description 55
- 201000005202 lung cancer Diseases 0.000 title abstract description 55
- 208000020816 lung neoplasm Diseases 0.000 title abstract description 55
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 110
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 20
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 12
- 239000002243 precursor Substances 0.000 claims description 43
- 102000001708 Protein Isoforms Human genes 0.000 claims description 18
- 108010029485 Protein Isoforms Proteins 0.000 claims description 18
- 239000000523 sample Substances 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 239000012472 biological sample Substances 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 11
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 claims description 6
- 102000018757 Apolipoprotein L1 Human genes 0.000 claims description 6
- 108010052469 Apolipoprotein L1 Proteins 0.000 claims description 6
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 6
- 102100032752 C-reactive protein Human genes 0.000 claims description 6
- 108010028777 Complement C8 Proteins 0.000 claims description 6
- 102100036154 Platelet basic protein Human genes 0.000 claims description 6
- 101710195957 Platelet basic protein Proteins 0.000 claims description 6
- 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 238000001819 mass spectrum Methods 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 102000016916 Complement C8 Human genes 0.000 claims 5
- 230000014509 gene expression Effects 0.000 abstract description 22
- 102100032007 Serum amyloid A-2 protein Human genes 0.000 abstract description 9
- 239000000090 biomarker Substances 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 239000003550 marker Substances 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 5
- 239000000439 tumor marker Substances 0.000 abstract description 5
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 101000637821 Homo sapiens Serum amyloid A-2 protein Proteins 0.000 abstract description 2
- 102000054727 Serum Amyloid A Human genes 0.000 description 20
- 108700028909 Serum Amyloid A Proteins 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 101710083332 Serum amyloid A-2 protein Proteins 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 5
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 5
- 239000001099 ammonium carbonate Substances 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101000869480 Homo sapiens Serum amyloid A-1 protein Proteins 0.000 description 4
- 102100032277 Serum amyloid A-1 protein Human genes 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000107 tumor biomarker Substances 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 102000009081 Apolipoprotein A-II Human genes 0.000 description 2
- 108010087614 Apolipoprotein A-II Proteins 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 238000011537 Coomassie blue staining Methods 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100035987 Leucine-rich alpha-2-glycoprotein Human genes 0.000 description 2
- 101710083711 Leucine-rich alpha-2-glycoprotein Proteins 0.000 description 2
- 238000010847 SEQUEST Methods 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000023769 AA amyloidosis Diseases 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000003780 Clusterin Human genes 0.000 description 1
- 108090000197 Clusterin Proteins 0.000 description 1
- 102100033772 Complement C4-A Human genes 0.000 description 1
- 108010077773 Complement C4a Proteins 0.000 description 1
- 102100040492 Complement component C8 gamma chain Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101000637835 Homo sapiens Serum amyloid A-4 protein Proteins 0.000 description 1
- 101000818517 Homo sapiens Zinc-alpha-2-glycoprotein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101001006906 Rattus norvegicus T-kininogen 1 Proteins 0.000 description 1
- 101001006907 Rattus norvegicus T-kininogen 2 Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101150026634 SAA3 gene Proteins 0.000 description 1
- 101710190759 Serum amyloid A protein Proteins 0.000 description 1
- 102100032016 Serum amyloid A-4 protein Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101000609411 Sus scrofa Inter-alpha-trypsin inhibitor heavy chain H4 Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000050760 Vitamin D-binding protein Human genes 0.000 description 1
- 101710179590 Vitamin D-binding protein Proteins 0.000 description 1
- 102100021144 Zinc-alpha-2-glycoprotein Human genes 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000000534 ion trap mass spectrometry Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S493/00—Manufacturing container or tube from paper; or other manufacturing from a sheet or web
- Y10S493/961—Tag, marker, or label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Computational Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Peptide identified | Peptides in common | ||
Compare 1 | LC1 | 21 | 17 |
N1 | 22 | ||
Compare 2 | LC2 | 18 | 13 |
N2 | 23 | ||
Compare 3 | LC3 | 28 | 19 |
N3 | 26 |
Claims (7)
- 보체 성분 C8 감마 쇄 전구체, 가상 단백질 DKFZp686C15213, 가상 단백질 DKFZp686N02209, 알파-1-안티키모트립신 전구체의 이소폼 1, 혈소판 베이직 단백질 전구체, SNC66 단백질, Ig lamda chain 단백질, C-반응 단백질 전구체의 이소폼 1 및 아포리포단백질-L1 전구체의 이소폼 2로 이루어진 그룹 중에서 1 내지 10개 선택되는 유전자에 특이적인 프라이머 쌍 또는 프로브를 포함하는 폐암 마커 검출용 조성물.
- 삭제
- 보체 성분 C8 감마 쇄 전구체, 가상 단백질 DKFZp686C15213, 가상 단백질 DKFZp686N02209, 알파-1-안티키모트립신 전구체의 이소폼 1, 혈소판 베이직 단백질 전구체, SNC66 단백질, Ig lamda chain 단백질, C-반응 단백질 전구체의 이소폼 1 및 아포리포단백질-L1 전구체의 이소폼 2로 이루어진 그룹 중에서 1 내지 10개 선택되는 유전자의 단백질에 특이적인 항체를 포함하는 폐암 마커 검출용 조성물.
- 보체 성분 C8 감마 쇄 전구체, 가상 단백질 DKFZp686C15213, 가상 단백질 DKFZp686N02209, 알파-1-안티키모트립신 전구체의 이소폼 1, 혈소판 베이직 단백질 전구체, SNC66 단백질, Ig lamda chain 단백질, C-반응 단백질 전구체의 이소폼 1 및 아포리포단백질-L1 전구체의 이소폼 2로 이루어진 그룹 중에서 1 내지 10개 선택되는 유전자에 특이적인 프라이머 쌍 또는 프로브를 사용하여 생물학적 시료내 상기 유전자의 mRNA 수준을 측정하는 단계를 포함하는, 폐암 마커를 검출하는 방법.
- 보체 성분 C8 감마 쇄 전구체, 가상 단백질 DKFZp686C15213, 가상 단백질 DKFZp686N02209, 알파-1-안티키모트립신 전구체의 이소폼 1, 혈소판 베이직 단백질 전구체, SNC66 단백질, Ig lamda chain 단백질, C-반응 단백질 전구체의 이소폼 1 및 아포리포단백질-L1 전구체의 이소폼 2로 이루어진 그룹 중에서 1 내지 10개 선택되는 유전자의 단백질에 특이적인 항체를 사용하여 생물학적 시료내 상기 유전자의 단백질 수준을 측정하는 단계를 포함하는, 폐암 마커를 검출하는 방법.
- 보체 성분 C8 감마 쇄 전구체, 가상 단백질 DKFZp686C15213, 가상 단백질 DKFZp686N02209, 알파-1-안티키모트립신 전구체의 이소폼 1, 혈소판 베이직 단백질 전구체, SNC66 단백질, Ig lamda chain 단백질, C-반응 단백질 전구체의 이소폼 1 및 아포리포단백질-L1 전구체의 이소폼 2로 이루어진 그룹 중에서 1 내지 10개 선택되는 유전자의 단백질에 대하여, 생물학적 시료내 절단된 펩타이드의 질량을 질량분석기를 이용하여 구하는 단계; 및 상기 펩타이드의 질량 스펙트럼을 단백질 서열 데이터베이스와 비교하여 생성된 펩타이드를 동정하는 단계를 포함하는, 폐암 마커를 검출하는 방법.
- 제 4항, 제 5 항 또는 제6항에 있어서, 생물학적 시료가 조직, 세포, 전혈, 혈청, 혈장, 타액, 객담 또는 뇨인 방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080070849A KR100899848B1 (ko) | 2008-07-21 | 2008-07-21 | 폐암 진단용 마커 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080070849A KR100899848B1 (ko) | 2008-07-21 | 2008-07-21 | 폐암 진단용 마커 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090036690A Division KR100925147B1 (ko) | 2009-04-27 | 2009-04-27 | 폐암 진단용 마커 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100899848B1 true KR100899848B1 (ko) | 2009-05-27 |
Family
ID=40862595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080070849A Expired - Fee Related KR100899848B1 (ko) | 2008-07-21 | 2008-07-21 | 폐암 진단용 마커 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100899848B1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013143940A1 (en) * | 2012-03-29 | 2013-10-03 | Proyecto De Biomedicina Cima, S.L. | New lung cancer molecular markers |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080064462A (ko) * | 2007-01-05 | 2008-07-09 | 경북대학교 산학협력단 | 신규한 폐암 진단용 마커 |
KR100846354B1 (ko) * | 2007-03-21 | 2008-07-15 | (주) 프로탄바이오 | 혈청 당단백질부터 분리한 폐암 진단용 마커 |
-
2008
- 2008-07-21 KR KR1020080070849A patent/KR100899848B1/ko not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080064462A (ko) * | 2007-01-05 | 2008-07-09 | 경북대학교 산학협력단 | 신규한 폐암 진단용 마커 |
KR100846354B1 (ko) * | 2007-03-21 | 2008-07-15 | (주) 프로탄바이오 | 혈청 당단백질부터 분리한 폐암 진단용 마커 |
Non-Patent Citations (2)
Title |
---|
Lung, 186, 255-261(online 2008.05.09.)* |
Proteomics, 5, 1062-1074(2005)* |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013143940A1 (en) * | 2012-03-29 | 2013-10-03 | Proyecto De Biomedicina Cima, S.L. | New lung cancer molecular markers |
US10545150B2 (en) | 2012-03-29 | 2020-01-28 | Proyecto De Biomedicina Cima, S.L. | Lung cancer molecular markers |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7285215B2 (ja) | 大腸がんを検出するためのバイオマーカー | |
KR101788414B1 (ko) | 간암 조기 진단용 바이오마커 및 그 용도 | |
US10345309B2 (en) | Biomarkers for gastric cancer and uses thereof | |
KR101073875B1 (ko) | 대장암 진단 마커 및 이를 이용한 대장암 진단방법 | |
KR100925147B1 (ko) | 폐암 진단용 마커 | |
JP4593117B2 (ja) | 炎症性疾患および敗血症を診断するための、カルバモイルリン酸シンテターゼ1(cps1)およびその断片の使用 | |
WO2006098464A1 (ja) | 前立腺がんの診断方法 | |
KR101527283B1 (ko) | 당단백질의 탈당화 검출을 통한 암 마커 스크리닝 방법 및 간세포암 마커 | |
JP4515099B2 (ja) | Lasp−1免疫反応性の決定によって炎症性疾患および感染を診断するための方法 | |
US20150338412A1 (en) | Composition for diagnosis of lung cancer and diagnosis kit for lung cancer | |
KR101995189B1 (ko) | 비침습적 체외진단을 위한 간암 진단용 바이오마커 조성물 및 이를 포함하는 키트 | |
KR100899848B1 (ko) | 폐암 진단용 마커 | |
KR101334123B1 (ko) | 소세포폐암 진단용 조성물 및 소세포폐암 진단키트 | |
EP2772759A1 (en) | Composition for diagnosis of lung cancer | |
KR102136643B1 (ko) | 신규한 간암 진단 마커 및 이의 용도 | |
KR102131860B1 (ko) | 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물 | |
WO2011138955A1 (ja) | Siaα2-8Siaα2-3Galβ-R糖鎖を持つムチン1の分析方法 | |
KR102519913B1 (ko) | 췌장 신경내분비 종양 진단용 바이오마커 조성물 및 이를 이용한 췌장 신경내분비 종양 진단에 필요한 정보를 제공하는 방법 | |
KR101054953B1 (ko) | 간암을 진단 및 치료하기 위한 분자인 snx14, 그를 포함하는 키트 | |
KR102009519B1 (ko) | 당뇨망막병증 진단용 마커 및 이의 용도 | |
KR20110068695A (ko) | 난소암에 대한 바이오마커 및 이를 이용한 난소암 진단 | |
KR20250059061A (ko) | 개의 림프종 진단용 조성물, 키트 및 정보 제공 방법 | |
KR20240009366A (ko) | 초기 알츠하이머병 진단용 바이오마커 및 이의 용도 | |
CN112415206A (zh) | 外泌体中的cd171蛋白作为肿瘤转移诊断标志物的应用 | |
KR20180024107A (ko) | 아토피 피부염 진단용 바이오마커 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20080721 |
|
PA0201 | Request for examination | ||
A302 | Request for accelerated examination | ||
PA0302 | Request for accelerated examination |
Patent event date: 20080814 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination Patent event date: 20080721 Patent event code: PA03021R01I Comment text: Patent Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20081103 Patent event code: PE09021S01D |
|
AMND | Amendment | ||
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20090303 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20081103 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
J201 | Request for trial against refusal decision | ||
PJ0201 | Trial against decision of rejection |
Patent event date: 20090402 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20090303 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20090512 Appeal identifier: 2009101003019 Request date: 20090402 |
|
A107 | Divisional application of patent | ||
AMND | Amendment | ||
PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 20090427 Patent event code: PA01071R01D |
|
PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20090427 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20090402 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20090105 Patent event code: PB09011R02I |
|
B701 | Decision to grant | ||
PB0701 | Decision of registration after re-examination before a trial |
Patent event date: 20090512 Comment text: Decision to Grant Registration Patent event code: PB07012S01D Patent event date: 20090507 Comment text: Transfer of Trial File for Re-examination before a Trial Patent event code: PB07011S01I |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20090521 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20090521 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20120521 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20120521 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20130327 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20130327 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150521 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20150521 Start annual number: 7 End annual number: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160520 Year of fee payment: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20160520 Start annual number: 8 End annual number: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180516 Year of fee payment: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20180516 Start annual number: 10 End annual number: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190521 Year of fee payment: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20190521 Start annual number: 11 End annual number: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20200521 Start annual number: 12 End annual number: 12 |
|
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20240301 |